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I. INTRODUCTION
T HE DEBATE about the role of government-funded research is roughly 400 years old [22] . However, additional studies are shedding new light on this discussion. Recently, researchers at the Science Policy Research Unit (SPRU), University of Sussex, East Sussex, U.K., conducted a literature review on the impact of publicly funded basic research on a variety of private industry performance outcomes [29] , [37] . Some of these outcomes have included the following:
1) industry and economy-wide economic performance; 2) new drugs; 3) formation of new companies; 4) direct increases in employment; 5) increasing the stock of useful knowledge; 6) training of skilled engineers and scientists. Thus, it appears that publicly funded research impacts the private sector in many ways; however, many researchers have uncovered very different findings from one another. The purpose of this paper is to provide the results of an extensive literature review with particular focus on the biomedical research areas. In addition, through an in-depth synthesis of the extant literature, this study seeks to uncover linkages, gaps, and new research opportunities.
There have been two related literature reviews done recently on the issue of economic benefits of publicly funded basic research. The first was by Martin and Salter of SPRU [29] . This report was conducted for Her Majesty's (HM) Treasury, and focused on three general methods for measuring the benefits of basic research: econometric studies, surveys, and case studies.
In the second paper [37] , the author order was changed and the report was shortened to more resemble a research paper. These previous works (hereafter, the SPRU papers) provided excellent foundations for the current research effort. However, this research effort has three noteworthy differences. First, the SPRU papers reviewed a substantial amount of the theoretical literature. While some important theories are examined, the primary emphasis of this paper will be on empirical work. Second, the SPRU papers reported any relationships across any industries regarding the role of publicly funded basic research. This paper will focus almost exclusively on the biomedical and biotechnology areas. Finally, and not surprisingly, there has been additional work done since the SPRU papers were written, and if fact, much of the research reviewed is currently in form of working papers. 1 
II. SEARCH METHODOLOGY
The SPRU papers provided significant assistance in the origin of this project. In addition, the documents' references yielded a substantial number of additional source papers to include.
Next, additional available databases that might highlight more articles to be incorporated were searched using multiple variations of key words such as "public funding," "biomedical," "biotechnology," and "performance." The timeframe utilized dated from the early 1990s to the year 2000, depending on how the particular database was structured.
Multiple sources were central to the effort. First, there were two subscription databases: ABI/INFORM and EconLit. Both of these are available through most commercial and academic research centers. In addition, three well-known websites, which contain relevant working papers, were reviewed. The first was the Maastricht Economic Research Institute on Innovation and Technology (MERIT) website (http://meritbbs.rulimburg.nl/). The second is housed at the Science Policy Research Unit (http://www.sussex.ac.uk/spru/) at the University of Sussex. The third was the U.S. National Bureau of Economic Research (NBER) (http://www.nber.org). Each of these websites yielded related papers or alternative source areas.
The final search was conducted at the offices of CHI Research Inc. (CHI), Haddon Heights, NJ. CHI is one of the world leaders in the areas of technology analyses, and in particular, publication and patent studies. Since the early 1970s, CHI has published over 100 scientific articles on publications, patents, and bibliometrics (citation counting). These factors mean that CHI has been actively involved in research on the public funding of basic research, and, therefore, has access to working papers, government reports, and memoranda that would be almost impossible to identify through traditional literature searches. CHI retains most of these documents and has a searchable database, called the KWOC, that resulted in additional papers and reports that supported this literature review.
At this point, we should clarify our working definition of publicly funded basic research. The publicly funded aspect is rather clear and was part of our search methodology in the various databases. The "basic" component is somewhat more problematic because we do make an assumption that most research funded by public sources tends to lean toward the basic versus applied end of the research spectrum. This is, of course, not entirely accurate, and recent research has shown that universities, who receive much of the public funding, are now doing more applied research. Yet, we feel that the further narrowing of our scope to examining only empirical papers in the biomedical area does offer some comfort with our definition. In recent research, McMillan et al. [30] examined the patenting and publication patterns of 119 U.S. biotechnology companies. In their patenting activities, these companies cited almost 7000 scientific papers, of which, 64% appeared in the most basic (versus applied) journals, and those papers received much of their funding from public sources (72%).
Additionally, to further elaborate on the framework we are utilizing, we note that though one of our assumptions is that the public funding of basic research is useful, economically supportable, and required due to the "public good" aspect of basic research, we concur with other researchers on the amount of support that may be required [3] . In their work with the Small Business Innovation Research Program (SBIR), the authors uncovered that SBIR funding stimulated private research and development (R&D), but that not all projects automatically require public dollars, and some would occur with no public funding. This approach suggests that though public funding may indeed be quite valuable, the public may over fund certain efforts that would otherwise be conducted by private companies. Further research in this important area is certainly warranted, yet this paper will just include this finding as part of our context.
III. SPRU PAPERS
Few papers rival the two SPRU studies in terms of both novelty and richness. The comprehensive nature of these papers required a substantial effort for the SPRU personnel to research and write the initial report for HM Treasury. In addition to Martin and Salter as the two lead authors, there were five other contributors to this work. Those five (Hicks, Pavitt, Senker, Sharp, and von Tunzelmann) are all very well known in fields of R&D management, science policy, and research evaluation. This breadth of talent focused on a narrow issue resulted in a formidable accomplishment. This literature review will begin with a brief summary of some of the report's primary findings.
The report begins with a discussion with the classic "public good" nature regarding the nature of economic benefits from basic research [11] . This line of reasoning suggests that basic research yields economically useful information that can be used by more than one firm to develop new products and processes. Since firms are unable to capture all the benefits from this basic research, they tend to under-invest in it, and the government should correct for the insufficient investment.
The report continues with a discussion of how that scientific knowledge is embedded in individuals and organizations, and the main benefits flow through training and networks. Public funding is needed to provide training and to maintain the nation's access to international networks of scientific knowledge. It appears that this publicly funded training concept permeates much of the SPRU research, both in these reviews and their other research.
Martin and Salter next describe the three main approaches they explored to measure economic benefits from basic research:
1) econometric studies (e.g., rates of return); 2) surveys (e.g., of the views of industrial R&D managers); 3) cases studies (e.g., tracing the research inputs to innovations). Virtually all the econometric attempts to estimate the impact of research on productivity have found positive rates of return, and in most cases, the effects have been comparatively high. Much of the historic review focuses on the work of Mansfield [26] - [28] . Mansfield estimated the social rate of return on basic research as 28%. He arrived at this estimate by examining U.S. gross profits from new products originating with recent academic research, an estimate of worldwide savings and gross profits from the same, and an estimate of the value to users of the new products. Though this 28% estimate is frequently cited, Mansfield himself admitted that it is very tentative and is based on "crude" calculations.
Another aspect of the econometric studies is the issue of public R&D as a complement (inducing) or a substitute (crowding out) for private R&D. A recent literature review of the subject [12] surveyed the body of econometric literature over the past 35 years. The authors developed a framework to organize and summarize the findings based on time-series and cross-sectional data from various levels of aggregation (laboratory, firm, industry, and country). They uncovered few examples of crowding out, except when firm-level data were employed.
Finally, in their review of both the surveys and case studies, Martin and Salter [29] highlighted the following six forms of economic benefits to basic research. 1) Basic research as a source of "public" information that serves to advance the overall body of knowledge. 2) The creation by basic researchers of new instrumentation and methodologies that are capital goods of the scientific research industry. These are the capital goods. Thus, they can be used to generate substantial economic returns. 3) Skills developed by those engaged in basic research, especially graduate students, yield economic benefits when in-dividuals move from academia to industrial research carrying codified and tacit knowledge. 4) Participation, particularly by private companies, in basic research to gain access to networks of experts and information. 5) The fact that basic research trainees may be particularly good at solving complex technological problems is an ability that often proves of great benefit in industry. 6) The creation of "spinoff" companies, particularly in biotechnology. The purpose of this paper is to more closely examine all of these benefits, but also to focus primarily those found in empirical papers on the biomedical and biotechnology areas.
IV. BASIC RESEARCH AS A SOURCE OF "PUBLIC" INFORMATION
One of the fundamental challenges in the analysis of publicly funded basic research centers on measurement. CHI has pioneered the use of bibliometrics to examine the impact of public funding on the generation and quality of papers and patents (public information). For example, Frame and Narin [15] provided one of the first comprehensive examinations of this issue. This study used the Science Citation Index for the publications and internal National Institutes of Health (NIH) data on funding for an observation period of 1965 to 1982. The sample included 229 major NIH-supported institutions, predominately universities.
Their findings were as follows. First, for a subset of 132 U.S. universities, they found a correlation of 0.95 between the amount of NIH funding and the number of biomedical publications. Second, for a subset of 52 hospitals, the correlation was 0.89 between the same two variables. Finally, for the total sample of 229, they discovered that the NIH provided 91% of the biomedical research support from major federal agencies, and more than half of the total external biomedical research support.
Two interesting observations emerged from these findings. One is that heavily funded universities publish more; they have more infrastructure, doctoral students, etc. (economies of scale). However, it is also possible that larger universities are less efficient than smaller ones, even though they get proportionally more funding (diseconomies of scale). Frame and Narin tested for both of these phenomena, and did not find support for either. While CHI has published over 100 research papers, including a large number during the 1980s and early 1990s, CHI made a major push in the mid-1990s to examine the relationship between science and technology. Perhaps their most important effort during this period was entitled "The Increasing Linkage between U.S. Technology and Public Science" [32] . In it, CHI examined the science references from all the U.S. patents from the years 1987-1988 and 1993-1994 . Similar to previous studies, they determined the source of the references (academia, industry, and government), and any funding sources that the papers acknowledged. This project's scale was enormous in comparison to previous CHI efforts. CHI's initial sample was 397 660 U.S. patents with 430 226 nonpatent references. Eventually, these nonpatent references were winnowed down to 242 000 scientific references, and further reduced to approximately 175 000 references covered by the Science Citation Index.
The final step in data acquisition was to identify the agencies supporting the U.S.-authored papers. A library search was undertaken for the 45 000 unique papers with at least one U.S. author. Of the cited papers found (95%), approximately 63% acknowledged some source of external support.
The central outcome was that 73% of the unique papers cited by U.S. industrial patents were from public science, i.e., authored at academic, governmental, and other public institutions. The New York Times [5] , as well as a host of other newspapers, reported this percentage. The industry breakdown was drugs and medicine (79%); chemicals (76%); and electronic components (49%).
It is apparent that public funding was quite prominent. For example, the National Cancer Institute was acknowledged as a funding source on 7970 biomedical citations (please note that an individual paper may be cited more than once). The next largest source was the National Heart, Lung, and Blood Institute with 4493 citations.
In addition to publishing a vast array of refereed articles, CHI has conducted a number of studies for the Office of Science Policy (OSP) at the NIH. Though some of those studies have been cited in CHI's published articles, many of them remain unpublished research reports. They are available upon request from the OSP. A brief discussion of four commissioned studies is provided in the following.
The first study examined all U.S. patents in 1993-1994 that cited NIH-supported science publications-95% of which fell into the drug and medicines category [34] . A second study examined the 1993-1994 patents with primary applications outside the medical arena (i.e., plant genetics, instruments, and advanced materials) that cite NIH-supported publications [35] . A third study examined the science underpinning of a sample of 55 drugs and vaccines that received "new drug approval" status from the Food and Drug Administration (FDA) between 1995 and 1996 [23] . This study was included because new drug approval is a step closer to commercial viability than is a patent. And finally, a fourth study examined recent patent activity in the field of "signal transduction and transciptional regulation," a rapidly growing area of basic science [24] .
The chief findings from these four studies confirm the general pattern observed in the other papers, including the particularly strong link between medically related patents and scientific research.
1) About 5000 of 223 000 U.S. patents issued in 1993-1994 cited some 20 000 times to 13 500 papers with NIH support. NIH supported more than half of the science citation in these patents. 2) Some 5% of all the patents that cited NIH-supported publications were applications outside of the immediate medical area. Thus, while not generally supporting research widely outside the medical arena, NIH-supported research is spinning off to other areas of significant commercial application. 3) Fifty-five drugs and vaccines received "new drug approval" status from FDA during 1995-1996. NIH support is substantial in the science base of these drugs. Of the 26 drugs in the sample with patent citing science papers, 46% have at least one patent that cites at least one paper whose research was supported by NIH. 4) An analysis of 62 signal transduction and transcriptional regulation related patents issued in 1995 showed that the patents in this field exhibit high-science linkage-some 26 nonpatent references per patent. By way of comparison, drugs and medicine patent as a general class in 1995 averaged 10.2 references per patent, and all patents regardless of the technology averaged just less than one nonpatent reference per patent. In addition, 60 of the 62 patents in the sample contain scientific journal references, and 90% of these cite at least one NIH-supported paper. In summary, over the past almost 30 years, CHI has provided us with a substantial amount of information and insight into this issue of the impact of public funding of basic biomedical research. They have found that: 1) basic biomedical research leads to publications; 2) NIH frequently funds the research that lead to the papers; and 3) that industrial patents frequently reference those publications. Thus, CHI has made great strides in empirically determining the relationship between basic research and public information.
V. CREATION BY BASIC RESEARCHERS OF NEW INSTRUMENTATION
The National Bureau of Economic Research (NBER) has conducted many important studies in the area of public funding of basic research, including new instrumentation. Toole [41] tested the importance of public science as a source of industrial innovation and measured its contribution to the biomedical industry. Toole combined two unique data sets: comprehensive information covering public biomedical research funding since 1955, and detailed data on new chemical entities (i.e., new drugs) approved by the FDA.
In his research, Toole first estimated that a 1% increase in the stock of public basic research ultimately leads to a 2.0%-2.4% increase in the number of commercially available new compounds. Second, he uncovered a lag between funding and commercialization of 17-19 years. Third, he estimated, using average cash flow estimates, that industry firms appropriate a return on public science investment of between 12%-41%. Finally, his data indicated, by way of a very strong negative time trend using dummy variables, that drug innovation has become more and more difficult over time. Toole suggested two reasons that drug discovery may be becoming more difficult. First, used opportunities are "fished out" and deplete the set of inventions; and second, new and unused opportunities become more expensive to pursue. This latter component reflects the increasing complexity of scientific inquiry.
VI. SKILLS MOVE FROM ACADEMIA TO INDUSTRIAL RESEARCH
The principal paper under this section is a theoretical piece done by Dasgupta and David [11] entitled "Toward a new economics of science." The authors described the importance of science policy and its role in national competitiveness and economic security. They argued that the previous economics literature regarding technological progress has been quite narrowly focused, and has lacked an overarching conceptual framework to guide empirical studies and public policy discussions. They offered their "new economics of science" model as a mechanism to remedy these deficiencies. Their model utilizes game theory, reward systems, and the behavioral norms of "open science" communities in an attempt to explain the advancement of science.
They also expressly addressed the issue of technology transfer from academia to industry. They supported Martin and Salter by focusing on the movement of academic scientists to industry as the primary means of technology transfer. Dasgupta and David articulated an interesting position on the impact of country immigration policies on this technology transfer process. They contended that many academic scientists, particularly the Ph.D. students, might be immigrants who will require sponsorship to work for a U.S. company. Toward this end, Dasgupta and David suggested that Western governments might want to reconsider their immigration policies.
Finally, they took special note of the increasing "secrecy" that seems to be occurring with scientific information, and provide a number of examples of how this phenomenon made indeed slow scientific and technological progress. A call for a resurgence of "open science" is probably the centerpiece of Dasgupta and David's ideas. A recent piece in The Atlantic Monthly dealt with the very same issue regarding openness [36] . The authors contend that commercially sponsored research is putting at risk the paramount value of higher education-disinterested inquiry. In addition, they provide examples of how universities are now behaving more like for-profit companies, all of which may diminish the advancement of the body of knowledge.
VII. PARTICIPATION BY COMPANIES TO GAIN ACCESS TO NETWORKS
By far the most frequently cited theoretical piece on how private firms make use of public research is Cohen and Levinthal's [10] absorptive capacity model. They argue that the ability of a firm to recognize the value of new, external, private, or public information, assimilate it, and apply it to commercial ends is critical to its innovative capability. Cohen and Levinthal go on to label this capability a firm's "absorptive capacity," and they suggest that it is largely a function of the firm's level of prior related knowledge. They formulate a model of firm investment in R&D, in which R&D contributes to a firm's absorptive capacity, which, in turn, allows the firm to access external information in such a way as to maximize their R&D capabilities. In addition to developing their model, Cohen and Levinthal test hypotheses using data from the Yale study [24] and the Federal Trade Commission's Line of Business Program, and they find general support for their model. The "absorptive capacity" model provides the foundation for many of the empirical articles discussed later.
An empirical study that draws significantly on Cohen and Levinthal was conducted by Cockburn and Henderson [6] who combined qualitative (in-depth surveys) and quantitative data to conduct an analysis of 21 "important" drugs (e.g., Tagamet, Proscar, Prozac, and Mevacor) and the public sector's role in their development. Their key finding was that only five of the 21 drugs were developed with no input from the public sector; one indication of the current importance of public funding. In addition, they uncovered was that companies who promote publication by their scientists were as much as 38% more productive in generating new drugs compared to those for whom publication was not part of their reward structure. Thus, building on the theory of absorptive capacity, their second finding supports the hypothesis that public researchers need to be connected to their private counterparts, and vice versa, that private publication is one means by which to accomplish that link.
A year later, Cockburn and Henderson [8] continued their examination of the 21 significant drugs. Their data included a program of interviews with senior managers and researchers at the pharmaceutical companies involved, and citation data from the Science Citation Index on the scientists working on the drugs. Coauthorship between those researchers in public institutions and company scientists was used as the measure of a firm's connectedness to the public sector.
They found that connectedness was significantly correlated with firms' internal organization (i.e., adopting an academic norm of encouraging publication by scientists), as well as their research performance in drug discovery (as measured by important patents per research dollar). 2 Thus, the ability to access and interact with public sector research activity is an important determinant of the productivity of "downstream" private sector research.
VIII. RESEARCH TRAINEES GOOD AT SOLVING TECHNOLOGICAL PROBLEMS
There have been a number of studies by researchers associated with the NBER that have examined issues of basic research, technology transfer, and public-private collaborations, and several focused solely on the biomedical area. In addition, many studies have employed patenting data. One of the first important ones was by Trajtenberg and colleagues [42] in which they explored the differences between university and corporate labs.
Trajtenberg and colleagues used patent citations to measure the "basicness" and "appropriability" of inventions. "Basic" research was characterized as "that which focuses on scientific rather than technological questions." They assumed that the basicness of research underlying an invention can be characterized by the nature of the previous patents cited by an invention; that the basicness of research outcomes relates to the subsequent patents that cite an invention; and that the fraction of citing patents that are assigned to the same organization as the original invention is a measure of appropriability. Their data set included all the university patents applied for in 1975 (316) and in 1980 (482), which gave the authors substantial times horizons backward and forward. This yielded data on the earlier (originating) patents, and on each of the subsequent patents citing them.
Using the quantity of subsequent patent citations as a measure of "basicness" of the inventions, the authors find that university research is indeed more basic and, therefore, harder to appropriate (note that most research trainees are in university settings). This finding is important in that federal agencies fund a substantial portion of the basic research done by universities; the NSF estimated the percentage as almost 60% in 1995 [33] . In addition, part of the mandate for those federal agencies is to "advance the body of knowledge." It appears that in the late 1970s and early 1980s, this effect was indeed happening.
Extending the previous research, Jaffe and Trajtenberg [20] conducted a comprehensive analysis of all U.S. patents from 1996 back to 1963 (2.5 million). They emphasized citation patterns looking at two issues: 1) which patents are highly cited by other patents and 2) are there geographic localization patterns of knowledge spillovers?
The authors presented four primary conclusions. First, they confirmed their previous findings regarding the importance or fertility of university patents. Second, they also confirmed their earlier work on the geographic localization of citations [21] . Third, they found that federal government patents are significantly less cited than corporate patents (2.9 average cites per patent versus 3.6), although they do have somewhat greater "staying power" over time. Finally, they showed that citation patterns across technological fields have gestation lags with electronics, optics, and nuclear technology showing very high early citation but rapid obsolescence, while drugs and medical technology generated significant citations for a very long time.
In an updated analysis of some of these findings, Henderson and colleagues [18] conducted a citation analysis of all the following sources: all university patents between 1965 and mid-1992 (12 804); a 1% random sample of all U.S. patents over the same period (19 535 ); all patents after 1974 that cited the university patents (40 859); and all patents after 1974 that cited the random sample patents (42 147). They found that although university patents were generally highly cited, their citation rate had been declining recently (the university versus random sample mean difference in importance, measured by citations, declined from over 2.5 in 1975 to 0 in 1988.) They concluded that universities are receiving a larger number of lower quality patents, and they further contended that the Bayh-Dole Act 3 had an adverse effect on university patenting. While the quantity of such patenting had increased significantly, the transfer of technology, in other than the raw amount of patenting, had not increased; it may even have declined. The authors argued that universities were attempting to directly generate commercial inventions, rather than focusing on new ideas that the private sector can commercialize. If true, this shift would be quite significant since universities have historically generated the radical new innovation ideas, which private industry then commercialized.
IX. CREATION OF "SPINOFF" COMPANIES
Building on Martin and Salter, our review includes an assessment of the public funding and the U.S. biotechnology industry. The rationale was very clear: many biotechnology companies (including the first one, Genentech) were primarily university spinoffs, where much of the basic research was funded by government agencies. In addition, the importance of biotechnology in the U.S. is becoming quite prominent; Ernst and Young reported in 1998 that there were 1274 public and private entities [14] .
Focusing on the issue of public funding, two research groups were instrumental in providing empirical insight into the workings of the biotechnology industry. Zucker and Darby, lead the first, while Audretsch and Stephan direct the second.
Partially funded by the NSF and the Sloan Foundation, Zucker and Darby collected a very large database on biotechnology firm characteristics and activities. Using these data, they developed a number of papers. In one of the first [43] , they examined the relationship between intellectual capital, defined by the authors as a specialized body of knowledge, which enables an individual to earn supranormal returns on the cost of obtaining that knowledge, and the creation of biotechnology firms. They identified 337 leading genetic sequence researchers (based on the number of genetic sequence discoveries reported up to 1990 for which they were an author and the number of such articles). Most of these researchers were affiliated with universities, and Zucker and Darby used the location of these researchers as a measure of regional intellectual capital. Their dependent variable was the timing and location of the births of biotechnology firms from 1976 to 1989.
They found that their intellectual capital measure (local number of highly productive star scientists) was predictive of the founding of new firms. In short, the presence of great universities was the key to the biotechnology revolution. While Zucker and Darby did not discuss this point directly, we have seen from other research in this review that public funding is very important to these research universities.
In two later papers, Zucker and Darby [44] , [45] extended the previous research and found that firms which were linked to academic "stars" were more successful (measured as products in development, products on the market, and employment growth) than those without such links. The most interesting result that emerged was that when the academic stars became involved with the firms, the researcher's publishing activity actually improved, when measured by citation analysis. The authors suggested that this relationship implies that commercial involvement may be a complement rather than a substitute for scientific productivity.
In parallel work, Audretsch and Stephan explored the importance of geographical proximity to major universities in the development of new biotechnology companies. In their 1996 paper, they examined the prospectuses of 54 biotechnology companies who went public between March 1990-November 1992 to determine location of the university-based scientists who had an affiliation with them [2] . Their findings, in contrast to Zucker and Darby's analyses, were that proximity does matter, but not that much. Almost 70% of the links between biotechnology companies and university-based scientists were nonlocal. A possible explanation to reconcile this finding with Zucker and Darby's is that Zucker and Darby focused mostly on founders of the companies, while Audretsch and Stephan were more interested in members of the science advisory boards (SABs).
Stephan [39] utilized the same data to test a hypothesis that the initial public offering (IPO) value of biotechnology firms is related to the human capital (reputation) embodied in the university-based scientists affiliated with the firm. She used two measures of reputation: the number of citations and the receipt of the Nobel Prize. Her findings were that IPO success was closely tied to the perceived ability of the scientists associated with the firm, and that reputation is an important lever by which funds are raised in biotechnology.
Finally, Audretsch and Stephan [1] examined knowledge movements from the scientists (principally university-based) to a new biotechnology firm. Using their prospectus database once more, they analyzed whether or not the star scientists retained their university employment, even though they were actively involved in a new company. They found that the stars could "cash out" by offering their services part-time to a firm, yet retain their university status. The authors suggested that this might reduce the amount of knowledge spillovers (information transfer) from the public to private sectors, compared to those that might occur if a star scientist moved completely into the private sector.
X. CONCLUSIONS, LIMITATIONS, AND RESEARCH OPPORTUNITIES
The purpose of this paper was to extend Martin and Salter's work by examining the literature on the public funding of biomedical research. Having now examined a wide array of articles on this subject, the following are some of our principal findings.
1) Public funding, particularly to universities, generates scientific publications, and those publications are a substantial portion of the science base on which the biomedical industry relies.
2) The public funding of university research also generates patents, but the process has shifted. Historically, highly cited university patents were mostly springboards for industry commercialization. Now universities directly seek the financial benefits from these innovations. As a result, universities patent much more frequently, but those patents generate significantly fewer citations, overall. [19] . 3) Spillovers from the public sector to the private occur, however, the private firms must have sufficient internal capability (absorptive capacity) for the process to work effectively. Public science is public, but it is not free. 4) The movement of trained scientific personnel from academia to industry is quite important in the technology transfer process. 5) Universities have played a substantial role in the emergence of the U.S. biotechnology industry, which has created new jobs, wealth, companies, and drugs. Having reviewed numerous papers that purport to illustrate the importance of the public funding of basic research, it is appropriate to also provide a counter view. In his book, The Economic Laws of Scientific Research, Kealey [22] contends that scientific research would do better without government support. In the course of making this controversial argument, he sets forth several "economic laws" of scientific research. The first law is a rise in R&D leads to a rise in GDP per capita, but rather that as per capita income grows, countries spend more on R&D because they can afford to do so. Given his first law, Kealey's second one is that public funding crowds out private support. Finally, his third law is that the net result of public spending on R&D is negative, and he uses the example of Japan, where there is little support of civilian R&D, with Britain, where there is a lot. He illustrates that Japan's high-tech industry is more competitive on world markets and that its spending on civilian R&D as a fraction of GDP is higher.
Though Kealey makes many interesting and important arguments, we side with many others of his critics who suggest that there are shortcomings to his approach. Perhaps the biggest problem with his model is that he simply assumes away any free-rider problems that might cause suboptimal spending on basic research. We believe that there is substantial evidence to indicate that the free-rider problem is real and does cause suboptimal spending. From this vantage point, continued public support for basic research seems both prudent and necessary.
Earlier in this section, we highlighted our findings from this literature search. One of the most critical concerns we now note concerns the issue of technology transfers. Since it seems quite clear that public funding creates knowledge and information in universities and government laboratories, it becomes important to see how that knowledge is transferred to the private sector. Bozeman [4] reviewed the research and theory on technology transfer, and argued that even though there are several hundred publications on the subject, under-researched topics remain. For example, he noted that we know little about the development of scientific and technical human capital, occurring over long periods of time. In addition, our knowledge of technology transfer activities and their effect on institutional design and capabilities is limited. Another interesting finding that may gain from new research efforts is the 1997 Cockburn and Henderson study of important drugs. While their overall findings supported the public funding hypothesis, there were the five out of 21 (24%) firms that did not use any public sector inputs. We might learn by studying these firms or drugs themselves, to understand the characteristics of the firms or their processes, which generated this conclusion. Finally, technology transfer politics, including distributional outcomes of technology-based economic development, deserve some future attention.
In addition to technology transfer issues, the evaluation of technology programs supported by various public agencies, which provide billions of dollars, require scrutiny about the return on those investments. Two recent articles provide insight into this area.
Scherer and Harhoff [38] explored the returns on a variety of German and U.S. inventions and innovations. They found that the returns were highly skewed, with the top 105 innovations in their sample of 772 German and 222 U.S. patents capturing anywhere from 48% to 93% of the total sample return. These findings suggested that programs seeking to advance technology should not be judged negatively if they lead to numerous failures; rather, emphasis should be placed on the relatively few big successes. This relationship is particularly true for governmental agencies that fund more basic R&D efforts.
In addition, Georghiou and Roessner [16] reviewed the various ways that public programs designed to stimulate technological inquiry are being evaluated. They discuss the following four methods of evaluation currently employed: 1) socio-economic impacts-tracing, bibliometrics, and econometrics; 2) linkages-cooperative research relationships between U.S. academic institutions and industry, as well as U.S. federal laboratories and industry; 3) collaborative R&D-case studies such as SEMATECH; 4) diffusion and extension programs-all 50 states in the U.S. now have at least one industrial modernization/extension program. Probably the most important point of the authors was that the passage in the U.S. of the Government Performance and Results Act (GPRA) in 1993 has galvanized the attention of the R&D community and the government regarding evaluation. They contend that the GPRA, with its mandate for near-term results, may shorten the time horizon of some publicly funded research efforts. The impact of this effect seems to be fertile ground for additional research.
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